Bob Babbitt shares some of his favorite stories collected from his years in the world of endurance sports. This episode shares the story of Jon Blais, Blazeman.
“alswarriorpoet-spirits”… even with their freedom, they, “fight the good fight”…the ultimate act of generosity, “so others may live”…G-D bless and FREEDOM!!! from ALS…(poet-spirits). University of Maryland Brain and Tissue Bank.
Brandeis University President, Ronald Liebowitz, appreciates the Blazeman Foundation for ALS for supporting Drs. Rodal and Deshpande (Blazeman Postdoctoral Fellow) over the past five years. He states “…you chose to support a postdoctoral fellowship, which will pay itself forward in research…” Please read his letter to the BMF.
The University of Maryland Brain and Tissue Bank acknowledges the recent expansion of the Blazeman ALS Tissue Collection and how this donation allows them to directly market the availability of ALS Tissue to researchers. This current fiscal year, ALS is ranked number one in terms of the number of samples they have shared from neurologic and developmental disease tissue. Future opportunities include working closely with the BMF to identify specific ALS investigators with whom they might establish a working relationship to expedite their research.
The BMF for ALS is pleased to announce the expansion of the Blazeman ALS tissue collection in collaboration with the University of Maryland Brain and Tissue Bank. This donation, made possible by your donations to the Foundation, will support the procurement of ALS tissue which is necessary for finding a cure.
A potential drug to treat motor neurone disease (MND) is set to emerge from a partnership between The University of Queensland and the Queensland Government.
University of Maryland Brain and Tissue Bank continues to promote the distribution of tissue from their Bank for ALS research to find a cure. The Bank has shipped more samples of ALS tissue over the past 5 months than the past 2 years combined!
The Mulligan Lab at Wake Forest University was working on a dose response study of the Hsp70 protein with the hopes that their ALS scientists and clinicians would be able to start to design initial clinical trials in patients. Unexpectedly, the protein does not prevent neuromuscular junction denervation in the mouse model of ALS.